title: Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma.
abstract: OBJECTIVE
  Intrahepatic recurrence frequently occurs in patients with hepatocellular carcinoma (HCC) even after successful percutaneous ethanol injection (PEI). This study investigated factors predicting recurrence after PEI for solitary HCC.
  
  
  METHODS
  The subjects were 31 patients with solitary HCC (10-29 mm) who received successful PEI. We investigated the relationship of pretreatment clinicopathological variables to recurrence-free survival including: age, gender, alcohol abuse, tumor size, tumor staining, tumor differentiation, serum alpha-fetoprotein (AFP) level, associated liver disease, and Child-Pugh classification. Differences in recurrence-free survival among subgroups classified by each factor were evaluated using log-rank tests.
  
  
  RESULTS
  Median recurrence-free survival time, 1 and 2 years recurrence-free survival rates of all 31 patients were 1.57 years, 72.2% and 45.4%, respectively. Among the 9 variables evaluated, serum AFP level of 20 ng/ml or less (p < 0.005) and absence of cirrhosis (p = 0.025) were factors favoring longer recurrence-free survival significantly.
  
  
  CONCLUSIONS
  These results indicate that HCC patients with higher serum AFP level or coexistent cirrhosis should be followed more closely even after successful PEI.
authors.affiliation: Department of Internal Medicine National Cancer Center Hospital, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ishii
authors.forename: S
authors.initials: S
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Nose
authors.forename: T
authors.initials: T
authors.lastname: Okusaka
authors.forename: H
authors.initials: H
authors.lastname: Nagahama
authors.forename: H
authors.initials: H
authors.lastname: Nakayama
authors.forename: H
authors.initials: H
authors.lastname: Nakasuka
authors.forename: M
authors.initials: M
authors.lastname: Yoshimori
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D018572:Disease-Free Survival; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008103:Liver Cirrhosis / Q000453:epidemiology; D008113:Liver Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011237:Predictive Value of Tests; D012307:Risk Factors; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins; D000431:Ethanol